|Bid||36.83 x 2200|
|Ask||36.90 x 3200|
|Day's Range||36.44 - 37.12|
|52 Week Range||27.62 - 37.12|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||9.78%|
|Beta (5Y Monthly)||1.94|
|Expense Ratio (net)||0.75%|
The race is on to find a cure for the deadly coronavirus and that competition could benefit some ETFs, including the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG). ARKG includes companies that ...
As investors look to growth opportunities ahead, many are looking to ongoing technological breakthroughs and targeted ETF strategies to capture these growing segments and enhance a diversified portfolio. ...
ARK Invest has identified five innovation platforms that are evolving today and causing an increased amount of new technological breakthroughs. Companies that are leading and benefiting from these technologies ...
Investors looking for the intersection of healthcare and disruption need to look to genomics and DNA sequencing, two of the core focuses of the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG). ARKG ...
Biotech firm Illumina, Inc. (ILMN) scrapped a merger with Pacific Biosciences, but there's still a lot to like about Illumina and for investors that can't handle the stock's over $300 price tag, the ARK Genomic Revolution Multi-Sector Fund (ARKG) is an adequate proxy on the stock. ARKG allocates 10.38% of its weight to shares of Illumina, making it the ETF with the largest weight to that stock. ARKG's stablemate, the ARK Innovation ETF (ARKK) , is second with an Illumina weight of about 7%.
With healthcare and, more specifically, biotechnology stocks and ETFs on the mend, investors may want to consider getting tactical and focusing on one of the arena’s most potent growth avenues: genomics. ...
ARK Investment Management LLC (ARK or ARK Invest), a New York-based investment adviser focused solely on disruptive innovation in the public equity markets, announced today plans to change the primary listing venue of the ARK Genomic Revolution ETF (ARKG) and the ARK Autonomous Technology & Robotics ETF (ARKQ) from the NYSE Arca, Inc. to the Cboe BZX Exchange, Inc. ARK anticipates that ARKG and ARKQ will begin trading on the Cboe BZX Exchange, Inc. under their current ticker symbols on December 31, 2019. No shareholder action is required as a result of this change.
Some money managers may loathe the idea of revealing their methodology in a fully transparent actively managed ETF, but others have fully embraced the investment vehicle to provide greater value to investors. ...
RK Genomic Revolution ETF is up more than 40% this year, making it one of the top ETFs of 2019. But to participate in that gain, investors had to time their buys carefully.
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.
For anyone not familiar with ARK Invest, they have a suite of ETF strategies dedicated to helping investors hone in on disruptive innovations and technologies with the potential to affect the global economy.
For anyone not familiar with ARK Invest, they have a suite of ETF strategies dedicated to helping investors hone in on disruptive innovations and technologies with the potential to affect the global economy. ...
There are new developments in DNA sequencing that are making a huge impact on healthcare and the direction of growth in the industry. To take advantage of this opportunity, investors can look to a targeted ETF strategy to gain exposure to this next generation of DNA sequencing. In the recent webcast, Next Generation DNA Sequencing: An Investor Field Guide, Simon Barnett, Analyst, Genomic Revolution, ARK Invest; and Tom Staudt, Chief Operating Officer, ARK Invest, sought to to size the potential investment opportunity in innovative technologies, notably those in the healthcare industry and DNA sequencing.
Next generation DNA sequencing could set the stage for a new era in medicine given its accuracy, cost-effectiveness, and soon—affordability. In the upcoming webcast, Next Generation DNA Sequencing: An ...
Kevin Cook joins us to help walk us through the maze that is the healthcare industry. We touch on everything from the hottest trends all the way down to how to pick a winning stock!
ETF investors who want to diversify into new areas of potential growth should identify areas of innovation and look to technologies that are disrupting the markets. On the recent webcast, Focusing on Disruptive ...